Binx Health, the pioneer in anywhere, anytime testing for women’s health, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its first-of-kind, highly sensitive and specific, molecular point-of-care (POC) diagnostic testing platform, the binx io®. The binx io platform is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the world’s first sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)—the two most tested-for STIs globally. In the Company’s recently completed 1,523-person, multi-center clinical study, 96% of patient samples were processed on the binx io by non-laboratorians in a POC setting.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
bacteria
binx health
Biosimilar
Blood Filter
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
colorectal cancer
Diagnostics
Digital Health
Drug Discovery
ExThera Medical
FDA
FDA approval
funding
fundraising
glycosylation
Halodoc
HIV
Innovation
Licensing
M&A
medical device
medtech
microbial
microbial DNA
microbial RNA
microbiome
Neuro
Novartis
pharma
Pharming
Prescient Metabiomics
robots
software
Therapeutics
Therapy
USA
VIrology
women health